NOVA Stock Chart & Stats
€42.90
€0.14(0.33%)
At close: 4:00 PM EDT
€42.90
€0.14(0.33%)
Day’s Range― - ―
52-Week Range€30.45 - €62.70
Previous CloseN/A
Volume50.00
Average Volume (3M)1.88K
Market Cap
€190.10B
Enterprise Value€182.73K
Total Cash (Recent Filing)€21.63B
Total Debt (Recent Filing)€146.38B
Price to Earnings (P/E)11.7
Beta0.73
Next Earnings
Aug 05, 2026EPS Estimate
0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)27.45
Shares Outstanding3,390,128,000
10 Day Avg. Volume1,276
30 Day Avg. Volume1,882
Financial Highlights & Ratios
PEG Ratio8.16
Price to Book (P/B)7.42
Price to Sales (P/S)4.66
P/FCF Ratio49.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€39.23Price Target Upside-8.55% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)2.88
Revenue Forecast (FY)€39.16B
Bulls Say, Bears Say
Bulls Say
Market-leading Wegovy FranchiseRapid, large-scale prescription uptake demonstrates durable demand and broad patient adoption for Novo Nordisk's oral GLP-1. High early penetration and large treatment base underpin structural revenue potential, strengthen bargaining position with payers, and create a high barrier to entry for competitors over the next several quarters.
Industry-leading ProfitabilityExceptionally high gross and net margins reflect strong pricing power, efficient scale manufacturing and favorable product mix. These structural profitability advantages support sustained operating cash generation, enable robust R&D funding and shareholder returns, and provide a buffer versus cyclical pricing pressures over months.
Robust Pipeline And ApprovalsSuccessful late‑stage results and multiple approvals diversify revenue beyond obesity/GLP‑1 into sickle cell disease, weekly insulin and other indications. This pipeline depth reduces reliance on a single franchise, expands addressable markets and supports medium‑term growth and resilience against regional pricing or access headwinds.
Bears Say
Rising LeverageMaterial increase in debt/equity tightens financial flexibility and raises interest‑rate sensitivity. Higher leverage limits the company's buffer to absorb prolonged revenue softness or higher funding costs, potentially constraining capital allocation choices and amplifying downside risk over the next several quarters.
Negative 2026 GuidanceManagement's guidance for year‑over‑year declines signals structural headwinds from pricing, reimbursement and LOE dynamics rather than a one‑off. Expected top‑line and operating profit contraction pressures reinvestment capacity and may prolong the moderation in growth and margins through the coming fiscal year.
Weaker Free‑cash‑flow ConversionDeclining and volatile FCF reduces sustainably available cash for R&D, M&A and shareholder returns without resorting to more debt. If the weaker cash conversion persists, the company may need to prioritize among strategic investments, buybacks and dividend policy, weakening financial optionality over the medium term.
Novo Nordisk News
NOVA FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was €30.45 and its highest was €62.70 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is €190.10B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Aug 05, 2026 which is in 9 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on May 06, 2026. The company reported €0.914 earnings per share for the quarter, beating the consensus estimate of €0.775 by €0.139.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Overvalued.
Does Novo Nordisk pay dividends?
Novo Nordisk does not currently pay dividends.
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.67.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of €0.914 in its last earnings report, beating expectations of €0.775. Following the earnings report the stock price went up 2.556%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in DE:NOVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novo Nordisk Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€39.23 (-8.55% Downside)
€39.23 (-8.55% Downside)
Blogger Sentiment
Bullish
DE:NOVA Sentiment 78%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.68%
12-Months-Change
Fundamentals
Return on Equity
3.64%
Trailing 12-Months
Asset Growth
21.75%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
NOVA Company Deck
NOVA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights very strong commercial and clinical momentum—especially for the Wegovy franchise (oral and high‑dose launches), positive pivotal and Phase II readouts (Etavopivat, UBT251), significant prescription uptake and clear execution on launches and shareholder returns. However, these commercial and R&D successes are balanced by meaningful near‑term financial headwinds: adjusted sales and operating profit declines, margin pressure from lower realized prices, pricing and reimbursement pressures (U.S. and international), guidance implying negative group growth for 2026, and supply/inventory nuances. Overall, product and pipeline momentum is robust, but the company faces material pricing and market access challenges that temper the near‑term financial outlook.View all DE:NOVA earnings summariesNOVA Stock 12 Month Forecast
Average Price Target
€39.23
▼(-8.55% Downside)